A detailed history of Golden State Equity Partners transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Golden State Equity Partners holds 200 shares of RLMD stock, worth $76. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Holding current value
$76
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$2.3 - $4.36 $459 - $872
200 New
200 $0
Q1 2023

Jun 01, 2023

SELL
$2.24 - $4.76 $27,720 - $58,905
-12,375 Closed
0 $0
Q1 2022

May 18, 2022

BUY
$16.72 - $26.99 $206,910 - $334,001
12,375 New
12,375 $334,000
Q1 2022

May 16, 2022

SELL
$16.72 - $26.99 $206,074 - $332,651
-12,325 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$16.93 - $26.82 $208,662 - $330,556
12,325 New
12,325 $278,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.